1. Scrip
  2. >>Business
  3. >>Deals

Eisai Regains Full Control Of ADC Program After Bristol R&D Reprioritization

 
• By Jessica Merrill

The Japanese pharma said it plans to accelerate development of the antibody-drug conjugate farletuzumab ecteribulin for solid tumors and will develop it independently.

paper rip
Eisai and Bristol ended an ADC collaboration • Source: Shutterstock

Eisai Co., Ltd.’s partnership with Bristol Myers Squibb Company on the antibody-drug conjugate farletuzumab ecteribulin (FZEC) appears to be a casualty of Bristol’s R&D prioritization program. Eisai announced the end of the three-year partnership on FZEC, formerly known as MORAb-202, on 1 July and said it plans to accelerate development of the product and conduct development and commercialization independently.

Key Takeaways
  • Eisai plans to accelerate development of farletuzumab ecteribulin after regaining full rights from Bristol Myers Squibb.

Bristol paid handsomely for rights to co-develop and co-commercialize FZEC in regions including the US, Europe and Asia in 2021....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Pfizer Wins Out In Metsera Bidding War

 
• By Mary Jo Laffler

Novo backs out, leaving Pfizer to complete its acquisition of the obesity specialist for nearly $3bn more than its initial offer.

Bavarian Nordic Future Looks Bright Despite Failed Takeover Bid

 
• By Kevin Grogan

Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.

Scrip M&A Podcast: What’s Next For Dealmaking In The Obesity Space?

 
• By Joseph Haas

With Sidley attorney Robert Darwin and EY economic analyst Arda Ural, Scrip looked at recent deals, the potential for more deals in the obesity space, and what type of assets might be most in demand.

Pfizer ‘Unwavering’ In Pursuit Of Metsera

 
• By Jessica Merrill

The big pharma remains committed to buying Metsera, even as the acquisition price has grown and some analysts pressed management on the value of the deal.

More from Business

Bavarian Nordic Future Looks Bright Despite Failed Takeover Bid

 
• By Kevin Grogan

Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.

Aurobindo On Easier US Biosimilar Pathway, Zentiva Miss And Deal Strategy

 
• By Vibha Ravi

Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call

Korean Biosimilars Giants Step Up Race To Become Innovators

 
• By Jung Won Shin

South Korea’s two biosimilars giants have laid out differing strategies to pursue innovative drug R&D, although both are positioning ADCs as a core focus.